Avadel v. Jazz Pharmaceuticals: Federal Circuit Reverses-in-Part, Vacates-in-Part on XYREM® Patents
Avadel CNS Pharmaceuticals challenged Jazz Pharmaceuticals over two sodium oxybate (XYREM®) patents — US11147782 and US10736866 — in a high-stakes Federal Circuit appeal. After 249 days, the court issued a split ruling: reversing in part, vacating in part, and remanding — reshaping the competitive landscape for sodium oxybate oral solution.
A Split Federal Circuit Ruling Reopens the XYREM® Patent Battle
Avadel CNS Pharmaceuticals, LLC filed this Federal Circuit appeal (Case No. 24-2278) on 30 August 2024, targeting Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited. At the core of the dispute are two formulation patents — US11147782 and US10736866 — both covering sodium oxybate oral solution, the active ingredient in XYREM®, a narcolepsy treatment with significant commercial value. The appeal arose from an infringement action and was heard by the Court of Appeals for the Federal Circuit.
The Federal Circuit closed the case on 6 May 2025 with a notably complex disposition: the lower court’s ruling was reversed in part, vacated in part, and remanded, while the appeal was simultaneously dismissed in part. This multi-pronged outcome means that some issues were resolved definitively in Avadel’s favour (reversed), others were nullified and sent back for reconsideration (vacated and remanded), and at least one aspect of the appeal did not proceed on the merits (dismissed in part).
A 249-day timeline from filing to disposition is broadly consistent with Federal Circuit appeal schedules for pharmaceutical patent disputes of this complexity. The split nature of the ruling — reversing, vacating, and remanding simultaneously — suggests the panel found meaningful legal error in at least part of the lower court’s analysis while declining to reach all issues. The precise scope of what was reversed versus vacated, and the specific claims or issues remanded, are not fully determinable from the public docket data alone, but the outcome clearly preserves live controversy between these parties at the district court level.
Filing to Appeal Dismissed in Part in 249 days
249-day appeal — consistent with an expedited Federal Circuit briefing schedule
Federal Circuit reverses-in-part and vacates-in-part: what the ruling means for both parties
Reversed-in-part, Vacated-in-part, Remanded: what each term does
A Federal Circuit reversal means the appellate panel found reversible legal error in the lower court’s decision on at least one issue, substituting a different outcome on that point. A vacatur nullifies the lower ruling without necessarily reaching a contrary conclusion, typically directing the district court to reconsider under corrected legal standards. Remand returns the case for further proceedings. All three occurring together signals a complex multi-issue appeal where the panel resolved some grounds definitively and left others open.
Multi-pronged appellate dispositionAvadel achieved partial reversal — a meaningful but incomplete appellate win
As appellant, Avadel CNS Pharmaceuticals secured a reversal on at least one issue, which is a substantive appellate victory — the Federal Circuit found the lower court erred in a manner that changes the outcome on that point. The vacatur-and-remand component also favours Avadel to the extent it prevents an adverse lower ruling from standing unchallenged. However, the partial dismissal of the appeal suggests Avadel did not prevail on all grounds it raised, and further district court proceedings will be required.
Partial win — remand requiredJazz faces renewed district court exposure on sodium oxybate patents
Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited could not fully defend the lower court’s ruling. The reversal on at least one issue is an adverse appellate finding, potentially affecting enforceability or validity conclusions concerning US11147782 or US10736866. The vacatur-and-remand means Jazz must re-litigate certain issues under corrected legal standards. The partial dismissal offers Jazz limited comfort, but the remand keeps live litigation pressure on the XYREM® franchise.
Adverse reversal — remand exposureSplit ruling prolongs sodium oxybate patent uncertainty for the sector
XYREM® (sodium oxybate) is a high-value narcolepsy therapy. A split Federal Circuit ruling — rather than a clean affirmance or reversal — prolongs commercial uncertainty for both branded competitors and any ANDA or NDA filers tracking this IP landscape. The remand means the district court will revisit contested claim scope or validity questions, potentially affecting market exclusivity timelines. Companies monitoring sodium oxybate formulation patents should treat this as a live and evolving enforcement risk.
Ongoing market exclusivity riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AVADEL CNS PHARMACEUTICALS, LLC | Company | CNS pharmaceutical company — holder of US11147782 and US10736866 (sodium oxybate formulations)Search in Eureka ↗ |
| Defendant | Jazz Pharmaceuticals, Inc. | Company | Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited — XYREM® originator and marketerSearch in Eureka ↗ |
| Co-Defendant | Jazz Pharmaceuticals Ireland Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Charles S. Dameron | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daralyn Jeannine Durie | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Gabriel K. Bell | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Herman H. Yue | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth G. Schuler | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kira Alexis Davis | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Marc Nathan Zubick | Attorney | Counsel for AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins LLP | Law Firm | Representing AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English, LLP | Law Firm | Representing AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster LLP | Law Firm | Representing AVADEL CNS PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | Ellyde R. Thompson | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Francis Dominic Cerrito | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Frank C. Calvosa | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Gabriel P. Brier | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Isaac SaidelGoley | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Quentin Jorgensen | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘REVERSED-IN-PART, VACATED-IN-PART, AND REMANDED’ — reflects a panel that found legal error of different characters across distinct issues. A reversal typically indicates the court reached a contrary conclusion on at least one claim; a vacatur indicates the lower ruling is nullified but the court declines to resolve the underlying question, returning it for further fact-finding or legal analysis under corrected standards. The simultaneous partial dismissal of the appeal suggests at least one issue was procedurally unreachable. At the Federal Circuit, the standard of review varies by issue — claim construction de novo, fact findings for clear error — meaning the reversal likely targeted a legal determination. The remand keeps both US11147782 and US10736866 in active dispute.
US11147782 & US10736866 — Sodium Oxybate Oral Solution Formulations
US11147782 (application US17/210064) and US10736866 (application US16/281235) are United States patents covering formulations of sodium oxybate oral solution — the active pharmaceutical ingredient in XYREM®, a controlled substance approved for the treatment of cataplexy and excessive daytime sleepiness associated with narcolepsy. Both patents sit within a formulation patent cluster that is strategically central to the commercial exclusivity of sodium oxybate products, including both Jazz’s originator XYREM® and Avadel’s competing product LUMRYZ.
Sodium oxybate formulation patents carry outsized commercial significance because they underpin market exclusivity for a product with annual revenues in the hundreds of millions of dollars. Competing CNS pharmaceutical companies, ANDA filers, and 505(b)(2) applicants tracking this space must assess both patents post-remand. The Federal Circuit’s split ruling suggests at least one claim boundary remains unsettled, elevating litigation risk for any developer of sodium oxybate oral formulations. The remand proceedings at district court level will likely determine whether specific formulation claims survive in their current scope.
Should you run an FTO against US11147782 and US10736866?
Any organisation developing, licensing, or commercialising sodium oxybate oral solution formulations — whether as a branded NDA, ANDA generic, or 505(b)(2) applicant — should treat both US11147782 and US10736866 as active FTO risk. The Federal Circuit’s remand means claim scope and validity remain judicially live. A product that cleared an FTO analysis based on the pre-appeal lower court ruling may need reassessment in light of the reversal and vacatur issued in May 2025.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11147782 and US10736866 against your sodium oxybate formulation, identify relevant prior art cited during prosecution and in the litigation, and surface related continuation or divisional filings that may carry additional risk. With the remand still pending, continuous patent monitoring — rather than a one-time FTO snapshot — is the appropriate posture for IP teams in this therapeutic area.
Run a freedom-to-operate analysis on US11147782 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Appeals in Pharmaceutical Formulation Patent Disputes
Federal Circuit appeals involving pharmaceutical formulation patents — particularly CNS and controlled-substance drug cases — follow distinct litigation patterns relevant to this Avadel v. Jazz dispute.
What this case signals for the sodium oxybate and CNS pharmaceutical IP landscape
A Federal Circuit split ruling on two sodium oxybate patents signals active, unresolved patent risk across the CNS drug formulation space.
Split Federal Circuit rulings signal prolonged litigation — model accordingly
When the Federal Circuit reverses-in-part, vacates-in-part, and remands, the dispute does not end — it returns to district court with new parameters. IP teams should assume that Avadel v. Jazz will continue to generate docket activity affecting US11147782 and US10736866 claims and any related ANDA or 505(b)(2) proceedings.
XYREM® patent portfolio remains actively contested — monitor both asserted patents
Both US11147782 and US10736866 remain judicially relevant post-remand. Any company developing, licensing, or marketing sodium oxybate oral solution formulations should track the district court remand proceedings closely, as claim construction or validity rulings on remand will directly shape freedom-to-operate positions in this therapeutic class.
AVADEL v Jazz — key questions answered
The Federal Circuit reversed-in-part, vacated-in-part, and remanded the case, while also dismissing the appeal in part. This means the court found reversible legal error on at least one issue concerning sodium oxybate patents US11147782 and US10736866, nullified the lower ruling on other issues, and returned the matter to the district court for further proceedings.
Two patents are central: US11147782 (application US17/210064) and US10736866 (application US16/281235). Both cover sodium oxybate oral solution formulations associated with the XYREM® narcolepsy treatment. Both patents remain judicially relevant following the Federal Circuit’s remand order.
A reversal means the Federal Circuit changed the lower court’s outcome on at least one issue — an appellate win for Avadel on that point. A vacatur nullifies the lower ruling on other issues without necessarily deciding them, sending those questions back to the district court under corrected legal standards. The remand means the litigation continues below, keeping both parties in active dispute.
The case involves sodium oxybate oral solution marketed as XYREM®. Both Avadel CNS Pharmaceuticals and Jazz Pharmaceuticals (including Jazz Pharmaceuticals Ireland Limited) have competing interests in this product. Avadel’s LUMRYZ is a competing sodium oxybate formulation, making patent exclusivity over formulation claims commercially critical for both parties.
Yes, it suggests FTO analyses based on the pre-appeal lower court ruling should be revisited. The reversal and vacatur indicate that claim scope or validity conclusions from the district court have been partially overturned or nullified. Any developer, generic applicant, or licensor assessing US11147782 or US10736866 should monitor the remand proceedings for updated claim scope determinations.
PatSnap Eureka searches patents and litigation data to answer instantly.